Known targets — ChEMBL curated mechanism
CHRM1CHRM2CHRM3CHRM4CHRM5SLC6A2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Choline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Choline SCHEMBL28623707 | 0.98 | CYP3A4 (0.46) | CYP3A4LMNACYP2D6MAPK1THPO | |
| Choline SCHEMBL28992902 | 0.96 | CYP3A4 (0.45) | CYP3A4LMNACYP2D6MAPK1THPO | |
| SCHEMBL2921887 | 0.91 | CYP3A4 (0.48) | CYP3A4LMNACYP2D6MAPK1THPO | |
| SCHEMBL10599444 | 0.89 | CYP3A4 (0.43) | CYP3A4LMNACYP2D6MAPK1THPO | |
| SCHEMBL11789370 | 0.89 | LMNA (0.46) | CYP3A4LMNACYP2D6MAPK1THPO | |
| SCHEMBL10503573 | 0.88 | LMNA (0.43) | CYP3A4LMNACYP2D6MAPK1THPO | |
| SCHEMBL10598903 | 0.86 | KCNH2 (0.45) | CYP3A4LMNACYP2D6MAPK1THPO | |
| SCHEMBL10598262 | 0.86 | KCNH2 (0.45) | CYP3A4LMNACYP2D6MAPK1THPO | |
| Choline SCHEMBL2150380 | 0.85 | ALDH1A1 (0.45) | CYP3A4LMNACYP2D6MAPK1SMN1; SMN2 | |
| Choline SCHEMBL9118969 | 0.85 | LMNA (0.43) | CYP3A4LMNACYP2D6MAPK1THPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 398 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120022522-A | Drug-loaded microneedle, drug-loaded microneedle patch and electrically-controlled drug release microneedle system | 成都邦迈医创科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-115636848-B | Method for synthesizing phosphorylcholine compound by one-pot method | 深圳翰宇药业股份有限公司 | 2024-11-29 | — | — | CN | claimed |
| US-11978622-B2 | Aqueous and semi-aqueous cleaners for the removal of post-etch residues with tungsten and cobalt compatibility | ENTEGRIS, INC. (US) | 2024-05-07 | — | — | US | claimed |
| CN-117866890-A | Preparation method for extracting and purifying adipose-derived mesenchymal stem cell exosomes | 山东翰康医学科技集团有限公司 | 2024-04-12 | — | — | CN | claimed |
| US-20230365602-A1 | COMPOUND FOR USE IN THE TREATMENT OF PROTOZOAL DISEASES AND PROCESS FOR PRODUCTION OF SAID COMPOUND | QUADREL S.R.L. (IT) | 2023-11-16 | — | — | US | claimed |
| EP-4216960-A1 | COMPOUND FOR USE IN THE TREATMENT OF PROTOZOAL DISEASES AND PROCESS FOR PRODUCTION OF SAID COMPOUND | Quadrel S.r.l. (IT) | 2023-08-02 | — | — | EP | claimed |
| CN-115636848-A | Method for synthesizing phosphorylcholine compounds by one-pot method | 深圳翰宇药业股份有限公司 | 2023-01-24 | — | — | CN | claimed |
| EP-4118079-A1 | PHARMACEUTICAL COMPOSITIONS OF LIPOIC ACID CHOLINE ESTER SALTS AND METHODS OF TREATMENT USING SAME | Novartis AG (CH) | 2023-01-18 | — | — | EP | claimed |
| CN-115279745-A | Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using the same | 诺华股份有限公司 | 2022-11-01 | — | — | CN | claimed |
| US-20220332978-A1 | Low Dishing Copper Chemical Mechanical Planarization | VERSUM MATERIALS US, LLC (US) | 2022-10-20 | — | — | US | claimed |
| EP-2088865-B1 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS INC (US) | 2015-10-21 | — | — | EP | claimed |
| WO-2015017659-A1 | AQUEOUS FORMULATIONS FOR REMOVING METAL HARD MASK AND POST-ETCH RESIDUE WITH Cu/W COMPATIBILITY | ADVANCED TECHNOLOGY MATERIALS, INC. (US) | 2015-02-05 | — | — | WO | claimed |
| US-20150027978-A1 | COMPOSITIONS AND METHODS FOR SELECTIVELY ETCHING TITANIUM NITRIDE | ADVANCED TECHNOLOGY MATERIALS, INC. (US) | 2015-01-29 | — | — | US | claimed |
| WO-2014138064-A1 | COMPOSITIONS AND METHODS FOR SELECTIVELY ETCHING TITANIUM NITRIDE | ADVANCED TECHNOLOGY MATERIALS, INC. (US) | 2014-09-12 | — | — | WO | claimed |
| US-7323601-B2 | Enanitomers of unsaturated alkyllysophosphonocholines and use as anti-neoplastics | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2008-01-29 | — | — | US | claimed |
| EP-1387847-A4 | ENANTIOMERS OF UNSATURATED ALKYLLYSOPHOSPHONOCHOLINES AND USE AS ANTI-NEOPLASTICS | UNIV CITY (US) | 2005-06-29 | — | — | EP | claimed |
| US-20050014971-A1 | Enanitomers of unsaturated alkyllysophosphonocholines and use as anti-neoplastics | UNIVERSITY OF MANITOBA, THE (CA) | 2005-01-20 | — | — | US | claimed |
| EP-1387847-A2 | ENANTIOMERS OF UNSATURATED ALKYLLYSOPHOSPHONOCHOLINES AND USE AS ANTI-NEOPLASTICS | The Research Foundation Of the City university of New York (US) | 2004-02-11 | — | — | EP | claimed |
| WO-2002067855-A2 | ENANTIOMERS OF UNSATURATED ALKYLLYSOPHOSPHONOCHOLINES AND USE AS ANTI-NEOPLASTICS | THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2002-09-06 | — | — | WO | claimed |
| WO-1995029923-A1 | PROCESS FOR THE PREPARATION OF MONO- AND BIS(PHOSPHOCHOLINE) DERIVATIVES WHICH HAVE ANTIFUNGAL ACTIVITY | SHAMAN PHARMACEUTICALS, INC. (US) | 1995-11-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014971-A1 | Enanitomers of unsaturated alkyllysophosphonocholines and use as anti-neoplastics | SGMS1, SGMS2, ENPP2 | CYP3A4 2257/4885LMNA 282/4885CYP2D6 1252/4885 |
| US-20230365602-A1 | COMPOUND FOR USE IN THE TREATMENT OF PROTOZOAL DISEASES AND PROCESS FOR PRODUCTION OF SAID COMPOUND | PIGO, PIGS, AGPS | CYP3A4 1129/4885LMNA 3079/4885CYP2D6 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.